Relative energy deficiency is well documented in Canadian athletes and almost entirely absent from Canadian shelf strategy. The sections being built to serve it are pointed at the slowest-growing products in the store.
Athlete under-fuelling has become a merchandising theme in Canadian natural health retail, and the sets being built around it share a common design: collagen for bone health, iron and calcium for depletion, omega-3 and turmeric for inflammation, an adaptogen for hormonal balance. Every one of those categories is either flat or declining. None of them carries a Health Canada claim that touches the condition. The demand is real and growing quickly. The shelf answer is aimed in the wrong direction.
The demand signal is unusually Canadian
The strongest applied dataset on the syndrome anywhere in the world was produced in Victoria, British Columbia. Researchers at Canadian Sport Institute Pacific ran the IOC’s Clinical Assessment Tool version 2 across 213 elite athletes and placed 55 per cent in the green category, 36 per cent yellow, five per cent orange and four per cent red. Athletes in the orange band carried nearly eight times the odds of a subsequent bone stress injury. A companion CSI Pacific study of 180 athletes put prevalence at 46 per cent.
The condition is also not what the merchandising shorthand assumes. A 2024 meta-analysis of 6,118 athletes found low energy availability in 44.2 per cent of women and 49.4 per cent of men, a numerically higher male rate. Elite Canadian female sprinters, not distance runners, showed indicator rates climbing from 31 per cent pre-season to 54 per cent after a five-month training block. Neither the sex nor the sport behaves the way the category assumes.
Underneath the elite tier sits a far larger commercial base. Canada’s professional women’s sports market has doubled since 2023 to between $380 million and $400 million, tracking toward $570 million by 2030, according to research from Canadian Women & Sport with Canadian Tire Corporation. In the same organization’s Rally Report, nearly one in two Canadian girls aged 13 to 18 said their menstrual cycle affects their participation in sport.
What the consensus actually says
Read the 2023 International Olympic Committee consensus statement looking for the supplement recommendations and there are none. Across 26 pages, no dietary supplement is recommended for any purpose. The only substantive mention of supplements places them in a differential-diagnosis column, among the alternative causes of low T3 that clinicians should rule out. Vitamin D appears exactly once, also as something to exclude when investigating low bone density.
What the panel does prescribe is food: “The primary approach to treating REDs should be a restoration of optimal EA via non-pharmacological approaches, including changes to diet and exercise.”
The statement, led by McMaster University’s Margo Mountjoy, also dismantles the number most retail messaging leans on. It walks back the familiar 30 kcal/kg fat-free mass threshold, warning of “risks in setting a definitive clinical threshold of EA due to many moderating factors,” and replaces it with a qualitative continuum from adaptable to problematic low energy availability. There is no longer a figure an athlete or a store can calculate. Assessment moved to CAT2, which requires fasted bloodwork, DXA imaging, eating-disorder questionnaire scoring and menstrual history, and whose own text states it “is not a substitute for professional clinical diagnosis, advice and/or treatment from a physician-led team.” An in-store or app-based risk quiz operates outside the tool’s stated conditions of use.
The evidence behind the corrective categories is thinner still. A 2026 systematic review of 13 experimental studies found no consistent changes in calcium metabolism, inflammatory markers or iron status under induced low energy availability. And in the only 12-month randomized controlled trial to raise energy intake in exercising women with menstrual dysfunction, spine and total-body bone density did not improve at all. If a supervised year of additional real food could not move bone density, no capsule can be sold as doing so.
The regulatory read: shared liability, and a runway
The monographs draw the line sharply, and it falls exactly where the popular sets are built. Hydrolyzed collagen carries permitted claims for osteoarthritis-related joint pain and amino acid content, and none for bone density. Fish oil permits cardiovascular, cognitive and triglyceride claims, and none for inflammation, soreness or recovery. Turmeric permits digestive, antioxidant and hepatoprotectant claims, and nothing about training load. Ashwagandha permits “adaptogen to help increase energy and resistance to stress,” and nothing about hormones or menstrual function. Health Canada published a hepatotoxicity safety review of oral ashwagandha in August 2026 that found insufficient evidence of a definite link but could not rule one out, having already declined the ingredient for supplemented foods in 2024.
Naming the syndrome makes it worse rather than better. Amenorrhoea, bone stress injury and low energy availability are clinical states with no authorized claim behind them, and depression and acute anxiety state both sit on Schedule A of the Food and Drugs Act, where section 3(1) prohibits advertising any product to the public as a treatment. Amenorrhoea is also a severe primary indicator under CAT2. Positioning an adaptogen as hormonal support for a woman who has stopped menstruating substitutes a product for a referral, which is the failure mode clinicians warn about most.
Retailers are not bystanders in any of this. Health Canada’s compliance policy applies to “every person that conducts an activity subject to the FDA,” names selling and advertising explicitly, and treats point-of-purchase material as advertising. A retailer who directly imports is treated as the importer. The Canadian Olympic and Paralympic Sport Institute Network is blunter: “Those who advise athletes about supplementation or those who provide supplements to athletes are equally liable.” Its list of qualified supplement advisors runs to three entries, and retail staff is not among them.
The same body supplies the runway. COPSIN confirms that an NPN “is not a designation to indicate that the supplement has been tested for banned substances,” while peer-reviewed work published in March 2026 estimates nine to 15 per cent of commercially available supplements carry undeclared prohibited substances. Under anti-doping strict liability, third-party certification is a merchandising asset a themed zone will never be, and it is the one organizing principle for an athlete set that survives legal review. As IHR noted when sport certification moved into the prenatal aisle, proof is becoming a condition of listing.
Where the money actually moved
The commercial case closes the argument. In SPINS US data, collagen showed zero per cent growth within sports protein, intra- and post-workout declined three per cent, and global omega-3 value fell 4.3 per cent in 2025 even as volume rose. Against that, US performance nutrition grew 22 per cent year over year to November 2025, hydration and electrolytes rose 29 per cent to US$2.2 billion, and creatine grew 77 per cent with a repeat-purchase rate near 50 per cent. Amazon searches for “creatine for women” now exceed 174,000 a month. Canadian scanner data for these subcategories is not published, which is worth stating rather than papering over, though the direction is consistent.
Carbohydrate is the quiet centre of it. The Workout Supplements monograph permits “source of carbohydrates to support energy production” and “helps to maintain performance/promote endurance in extended (greater than 60 min), high intensity exercise.” That is the closest any authorized Canadian claim comes to speaking to an under-eating athlete, and it is a performance claim rather than a treatment claim. Protein sits beside it with clean claims for tissue repair and lean mass.
A second doorway leads to the same fixture. Leger research fielded in February 2026 found three million Canadian adults taking GLP-1 medications, over half reporting decreased appetite and a third buying more protein-rich food. That is a managed energy deficit with elevated nutrient-density needs, arriving with an entirely different story. With semaglutide’s Canadian patent expired and generics entering through 2026, that volume lands in the dispensary precisely when the national guidance is silent: the 2025 Canadian obesity pharmacotherapy guideline update offers no implementation detail on protein or lean-mass preservation, and does not mention pharmacists at all. The prescription and the answer are thirty feet apart, with no protocol connecting them.
The pharmacy counter has a licence the health food store does not
This is where the two halves of the trade diverge sharply, and where the more interesting commercial opportunity sits.
British Columbia’s own provincial guideline on iron deficiency names “endurance athletes” and “those with disordered eating” in a single sentence listing who to test, and specifies the two tests that answer the question: serum ferritin and a CBC. Since August 2024, BC pharmacists have been designated referring practitioners able to order both from a 42-test schedule, free to MSP beneficiaries. The catch is that BC ties ordering to assessing or monitoring drug therapy, so a walk-in athlete on no medication falls outside it.
Alberta has no such limit. Alberta pharmacists need no additional prescribing authorization to order lab tests, there is no list of permitted tests, and the governing standard allows ordering to identify a condition, not merely monitor a drug. An Alberta pharmacist with additional prescribing authorization can order a ferritin and CBC on a fatigued runner, interpret the result, prescribe oral iron and refer onward, entirely in-store. No other province permits the full sequence. Ontario and Saskatchewan pharmacists cannot order lab tests at all as of September 2026, and Nova Scotia explicitly refuses bloodwork unrelated to a medication under assessment.
None of this is being used. In a survey of Canadian university athletes, 75.6 per cent regarded pharmacists as a good source of information on banned substances; 37.7 per cent actually consulted one. The study is a decade old and single-institution, so treat it as directional, but the shape of the gap has not obviously changed. Athletes trust the counter and walk past it.
Two absences make the opening wider. No province’s minor-ailments list includes anemia, iron deficiency, fatigue or menstrual irregularity. And no Canadian pharmacy standard, directive or continuing-education module anywhere mentions relative energy deficiency, the female athlete triad, amenorrhoea or stress fracture, nor does any Canadian body publish guidance for pharmacists on recognizing disordered eating. The duty to refer is real and enforceable under provincial standards; the training to know when is not supplied by anyone.
For independents without a dispensary, the arithmetic is different and the honest answer is narrower. Canada’s health stores generated $4.2 billion in 2025 while growing at 0.5 per cent annually against category growth of seven to eight per cent, with Popeye’s Supplements and Supplement King contesting the athlete customer from over 100 locations each. Testing is not available to them, and a curated section will not win that fight. What does travel is the referral relationship, built in the other direction: a named dietitian, sports physician or pharmacy to send people to, and a floor team that recognizes when a sale is the wrong response. Amenorrhoea, repeated stress fractures, rapid weight loss and restrictive eating are the triggers, and NEDIC is the national referral point.
That protocol has to be written in-house, because no Canadian guidance exists on it for retail either. Not from Health Canada, not from CHFA, not from any provincial college, not from NEDIC itself. For a trade that sells to athletes every day, four separate bodies have left the same gap, and it is worth raising with all of them.
Frequently Asked Questions
What is REDs, and how does it differ from RED-S?
REDs stands for Relative Energy Deficiency in Sport, a syndrome of impaired physiological and psychological function caused by prolonged or severe low energy availability. The 2023 IOC consensus statement changed the acronym from RED-S to REDs for improved comprehension and dissemination. It affects both male and female athletes and requires a physician-led diagnosis.
Can a Canadian retailer market supplements for REDs or low energy availability?
No. No Health Canada monograph authorizes a claim referencing REDs, low energy availability, amenorrhoea or bone stress injury. Presenting a product as addressing those conditions is an unauthorized treatment claim, and point-of-purchase and social material both count as advertising under Canadian consumer health product advertising guidelines.
Does a Natural Product Number mean a supplement is safe for drug-tested athletes?
No. Canada’s sport institute network states plainly that an NPN indicates safety, quality and claims review under Health Canada criteria, but is not a designation that a product has been tested for banned substances. Athletes carry strict liability, so third-party certification through NSF, Informed Sport or BSCG remains the relevant assurance.
Which product categories can retailers legitimately merchandise to under-fuelled athletes?
Those with authorized claims under the Workout Supplements monograph: carbohydrates for energy production and endurance in sessions over 60 minutes, protein for tissue repair and lean muscle, creatine for strength and power, and electrolyte sources. These are fuelling claims rather than treatment claims, and they align with the consensus position that restoring energy intake comes first.
Can a Canadian pharmacist order iron tests for an athlete?
It depends on the province. Alberta pharmacists may order ferritin and CBC to identify a condition, with no restricted test list. British Columbia pharmacists may order both, but only in connection with assessing or monitoring drug therapy. Ontario and Saskatchewan pharmacists cannot order laboratory tests at all as of September 2026.
This is independent editorial analysis from IHR Magazine, written for retailers and brand managers. It is not clinical guidance and not a substitute for medical advice. REDs is diagnosed by a physician-led multidisciplinary team, and retailers should verify current NPN status and authorized claims before making purchasing or marketing decisions.
